Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 ± 2.26 and 19.1 ± 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 ± 0.32 and 0.46 ± 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 ± 0.35 and of group 2 0.16 ± 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up.

Keywords:
Thermal laser, Age-related macular degeneration, Extrafoveal choroidal neovascularization, Ranibizumab
1.
Spitzer MS, Ziemssen F, Bartz-Schmidt KU, Gelisken F, Szurman P: Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol 2008;2:1–14.
2.
Beaumont PE, Kang HK: Lesion morphology in age-related macular degeneration and its therapeutic significance. Arch Ophthalmol 2006;124:807–812.
3.
Macular Photocoagulation Study Group: Argon laser photocoagulation for senile macular degeneration: results of a clinical randomized trial. Arch Ophthalmol 1982;100:912–918.
4.
Coscas G, Soubrane G: Photocoagulation des néovaisseaux sousrétiniens dans la dégénérescence maculaire sénile par laser à argon: résultats de l’étude randomisée de 60 cas. Bull Mem Soc Fr Ophtalmol 1983;94:149–154.
5.
Macular Photocoagulation Study Group: Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1990;108:816–824.
6.
Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220–1231.
7.
Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular lesions of age-related macular degeneration: five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109–1114.
8.
Macular Photocoagulation Study Group: Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109:1242–1257.
9.
Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200–1209.
10.
Macular Photocoagulation Study Group: Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994;112:480–488.
11.
Macular Photocoagulation Study Group: Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500–509.
12.
Macular Photocoagulation Study Group: Occult choroidal neovascularization: influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996;114:400–412.
13.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials. TAP Report 1. Arch Ophthalmol 1999;117:1329–1345.
14.
Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials. TAP Report 2. Arch Ophthalmol 2001;119:198–207.
15.
Wachtlin J, Stroux A, Wehner A, Heimann H, Foerster MH: Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV. Graefes Arch Clin Exp Ophthalmol 2005;243:438–445.
16.
Voelker M, Gelisken F, Ziemssen F, Wachtlin J, Grisanti S: Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005;243:1241–1246.
17.
Mikuni E, Shimada H, Mori R, Nemoto A, Yuzawa M: Surgical removal of juxtafoveal and extrafoveal choroidal neovascularization in age-related macular degeneration. Nippon Ganka Gakkai Zasshi 2003;107:695–701.
18.
Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387–1394.
19.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
20.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.
21.
Bhatnagar P, Spaide RF, Takahashi BS, Peragallo JH, Freund KB, Klancnik JM Jr, Cooney MJ, Slakter JS, Sorenson JA, Yannuzzi LA: Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;27:846–850.
22.
Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583.
23.
Spaide R: Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679–680.
24.
Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239–248.
25.
Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group: Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868–1875.
26.
Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR: Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850–857.
27.
Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246–252.
28.
Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43–58.
29.
Ladas ID: Use of digitized fluorescein angiogram system to guide laser treatment of diabetic macular edema: a new technique. Ophthalmologica 2003;217:194–198.
30.
Ladas ID, Rouvas AA, Apostolopoulos M, Brouzas D, Karagiannis DA, Georgalas I, Baltatzis S: Diffuse retinal pigment epitheliopathy: treatment with laser photocoagulation. Eur J Ophthalmol 2004;14:315–320.
31.
Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J: A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 2009;29:1444–1449.
32.
Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ: Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye 2010;24:713–716.
33.
Zarbin M, Szirth B: Current treatment of age-related macular degeneration. Optom Vis Sci 2007;84:559–572.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.